PD
AXSM icon

Point72 (DIFC)’s Axsome Therapeutics AXSM Stock Holding History

Point72 (DIFC)’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$68.5K Buy
+564
New +$63.5K ﹤0.01% 669
2025
Q2 		– Sell
-4,600
Closed -$537K – 1557
2025
Q1 		$537K Buy
4,600
+822
+22% +$93.6K 0.02% 625
2024
Q4 		$320K Buy
+3,778
New +$347K 0.01% 763

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 (DIFC)'s AXSM Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in Axsome Therapeutics (AXSM) in Q3 2025: 564 shares worth $68.5K. The stake represents ﹤0.01% of the portfolio and ranks #669 among its holdings. This is a return to the name: Point72 (DIFC) previously reported a position in AXSM as recently as Q1 2025.

Point72 (DIFC) first reported a position in AXSM in Q4 2024 and has held it in 3 quarters since. The position peaked at $537K in Q1 2025. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Point72 (DIFC) held 564 shares of Axsome Therapeutics worth $68.5K as of Q3 2025.
  • Axsome Therapeutics was a new Point72 (DIFC) position in Q3 2025.
  • Axsome Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #669 holding.
  • Point72 (DIFC) first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Point72 (DIFC)'s Axsome Therapeutics position peaked at $537K in Q1 2025.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.